AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10865690 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared group
Number of subjects: 86
Study 10865690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 8532902 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary chain irradiation (IMC‐RT)
Number of subjects: 270
Study 8532902 — intervention group
Group type: COMPARATOR
Intervention: No internal mammary chain irradiation (no‐IMC‐RT)
Number of subjects: 270
Study 2184938 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 28
Study 2184938 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril combined with diltiazem
Number of subjects: 28
Study 2184938 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 28
Study 40816 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazepam (0.0025 mg/kg)
Number of subjects: 32
Study 40816 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.005 mg/kg)
Number of subjects: 32
Study 31589776 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (n = 32)
Number of subjects: 64
Study 31589776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 64
Study 28390867 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI2070 (700 mg) at weeks 0 and 4, followed by open-label MEDI2070 (210 mg) subcutaneously every 4 weeks from weeks 12 to 112
Number of subjects: 119
Study 28390867 — intervention group
Group type: COMPARATOR
Intervention: Open-label MEDI2070 after placebo
Number of subjects: 119
Study 26303135 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based parenting support for attachment, delivered until 6 months postpartum
Number of subjects: 449
Study 26303135 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 449
Study 24859954 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticle group
Number of subjects: 40
Study 24859954 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 22642182 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session MOHO program
Number of subjects: 220
Study 22642182 — intervention group
Group type: COMPARATOR
Intervention: 15-session crafts program or no treatment
Number of subjects: 220
Study 20673485 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-chemotherapy tumor extent (GTV-T) irradiation
Number of subjects: 77
Study 20673485 — intervention group
Group type: COMPARATOR
Intervention: Pre-chemotherapy tumor extent (GTV-T) irradiation
Number of subjects: 77
Study 18397701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (30 - 180 mg/day)
Number of subjects: 32
Study 18397701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15849845 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg IV
Number of subjects: 40
Study 15849845 — intervention group
Group type: COMPARATOR
Intervention: Control (2 ml saline IV)
Number of subjects: 40
Study 12418585 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled oxitropium bromide 200 microg
Number of subjects: 236
Study 12418585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release oral theophylline 300 mg
Number of subjects: 236
Study 12418585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxitropium bromide and theophylline
Number of subjects: 236
Study 12418585 — intervention group
Group type: COMPARATOR
Intervention: Control group (theophylline alone)
Number of subjects: 236
Study 10628627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 102
Study 10628627 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 102
Study 7862382 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the Camper fascia
Number of subjects: 245
Study 7862382 — intervention group
Group type: COMPARATOR
Intervention: No closure of Camper fascia
Number of subjects: 245
Study 1412152 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg, i.v.)
Number of subjects: 92
Study 1412152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 4014796 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg ergometrine by slow intravenous injection
Number of subjects: 113
Study 4014796 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 units oxytocin in intravenous infusion throughout the procedure
Number of subjects: 113
Study 4014796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxytocic drugs)
Number of subjects: 113
Study 30796153 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous computed tomography‐guided cordotomy
Number of subjects: 16
Study 30796153 — intervention group
Group type: COMPARATOR
Intervention: Continued interdisciplinary palliative care
Number of subjects: 16
Study 30427933 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endurance and resistance training combined with mobilisation
Number of subjects: 115
Study 30427933 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy including early mobilisation
Number of subjects: 115
Study 26370095 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives of up to £400 vouchers contingent upon smoking cessation
Number of subjects: 612
Study 26370095 — intervention group
Group type: COMPARATOR
Intervention: Usual cessation support
Number of subjects: 612
Study 26370095 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives of up to £400 vouchers
Number of subjects: 612
Study 24287124 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (experimental group 1)
Number of subjects: 2001
Study 24287124 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention supplemented with text messages (experimental group 2)
Number of subjects: 2001
Study 24287124 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2001
Study 23725092 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical + Lifestyle Programme (MLP)
Number of subjects: 314
Study 23725092 — intervention group
Group type: COMPARATOR
Intervention: Medical Programme (MP)
Number of subjects: 314
Study 21436229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MITOX) monthly (12 mg/m²; maximum 20 mg) combined with 1 g of methylprednisolone (MP) for 6 months followed by interferon beta-1b (IFN) for the last 27 months
Number of subjects: 109
Study 21436229 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1b (IFN) for 3 years combined with 1 g of methylprednisolone (MP) monthly for the first 6 months
Number of subjects: 109
Study 19959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sunlight with calcium supplementation
Number of subjects: 0
Study 19959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (vitamin K2) plus calcium and vitamin D supplementation
Number of subjects: 0
Study 19959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate plus calcium and vitamin D supplementation
Number of subjects: 0
Study 17511904 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment using modified Luque III instrumentation
Number of subjects: 120
Study 17511904 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with various fixation techniques
Number of subjects: 120
Study 17511904 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative scoliosis ranking
Number of subjects: 120
Study 17511904 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with anterior and posterior approaches
Number of subjects: 120
Study 17511904 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 120
Study 15356403 — intervention group
Group type: EXPERIMENTAL
Intervention: Levormeloxifene (5 mg/kg/day)
Number of subjects: 301
Study 15356403 — intervention group
Group type: EXPERIMENTAL
Intervention: Levormeloxifene (0.2 mg/kg/day)
Number of subjects: 301
Study 15356403 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 301
Study 15356403 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 301
Study 15356403 — intervention group
Group type: COMPARATOR
Intervention: Sham operation
Number of subjects: 301
Study 11438314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 CEE
Number of subjects: 749
Study 11438314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 CEE/2.5 MPA
Number of subjects: 749
Study 11438314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 CEE
Number of subjects: 749
Study 11438314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 CEE/2.5 MPA
Number of subjects: 749
Study 11438314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 CEE/1.5 MPA
Number of subjects: 749
Study 11438314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 CEE
Number of subjects: 749
Study 11438314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 CEE/1.5 MPA
Number of subjects: 749
Study 11438314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study 9679514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-knowledge (HK) readers received passage titles that clarified the content.
Number of subjects: 0
Study 9679514 — intervention group
Group type: COMPARATOR
Intervention: Low-knowledge (LK) readers did not receive passage titles.
Number of subjects: 0
Study 9679514 — intervention group
Group type: COMPARATOR
Intervention: Older LK readers who were above average in recall.
Number of subjects: 0
Study 7726670 — intervention group
Group type: EXPERIMENTAL
Intervention: Beger technique
Number of subjects: 42
Study 7726670 — intervention group
Group type: EXPERIMENTAL
Intervention: Frey technique
Number of subjects: 42
Study 2033963 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR)
Number of subjects: 164
Study 2033963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (DHAD)
Number of subjects: 164
Study 2033963 — intervention group
Group type: COMPARATOR
Intervention: CNS prophylaxis with intermediate dose methotrexate (MTX) and intrathecal MTX
Number of subjects: 164
Study 6803279 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (50‐200 mg/day)
Number of subjects: 17
Study 6803279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (40‐100 mg/day)
Number of subjects: 17
Study 6803279 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine with perphenazine (8‐16 mg/day)
Number of subjects: 17
Study 6803279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline with perphenazine (8‐16 mg/day)
Number of subjects: 17
Study 30178432 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 93
Study 30178432 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physical Therapy (CPT)
Number of subjects: 93
Study 30178432 — intervention group
Group type: COMPARATOR
Intervention: Exercise Therapy (ET)
Number of subjects: 93
Study 28651648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic oxygenation (FIO2 necessary to maintain arterial hemoglobin saturation of 95 to 97%)
Number of subjects: 200
Study 28651648 — intervention group
Group type: COMPARATOR
Intervention: Hyper‐oxygenation (FIO2 = 1.0)
Number of subjects: 200
Study 28651648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic oxygenation
Number of subjects: 200
Study 28651648 — intervention group
Group type: COMPARATOR
Intervention: Hyper‐oxygenation
Number of subjects: 200
Study 26436533 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive truncated weighting method for estimating weights in marginal structural models (MSMs)
Number of subjects: 0
Study 26436533 — intervention group
Group type: COMPARATOR
Intervention: Traditional time-dependent Cox models
Number of subjects: 0
Study 23399476 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with the intervention package (nurse-led consultations and peer support)
Number of subjects: 306
Study 23399476 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 23399476 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with the intervention package
Number of subjects: 306
Study 21933834 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerator magnet and text message emphasizing benefits to society
Number of subjects: 1041
Study 21933834 — intervention group
Group type: COMPARATOR
Intervention: Standard reminder regarding follow-up
Number of subjects: 1041
Study 21933834 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call from a senior female clinician and researcher
Number of subjects: 1041
Study 21933834 — intervention group
Group type: COMPARATOR
Intervention: Standard Txt2stop follow-up procedures
Number of subjects: 1041
Study 20048503 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 20048503 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea monotherapy
Number of subjects: 0
Study 17575542 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic function test (ePFT)
Number of subjects: 33
Study 17575542 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour pancreatic function test (2hPFT)
Number of subjects: 33
Study 17575542 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study 14731120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon (IFN)-alpha 2b (10 MU/m2) thrice/weekly for 6 months
Number of subjects: 182
Study 14731120 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (5 MU/m2) thrice/weekly for 6 months + Lamivudine (LAM) (4 mg/kg, max 100 mg/day) for 12 months (started simultaneously with IFN)
Number of subjects: 182
Study 14731120 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (5 MU/m2) thrice/weekly for 6 months + Lamivudine (LAM) (4 mg/kg, max 100 mg/day) for 12 months (started 2 months prior to IFN)
Number of subjects: 182
Study 14731120 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 182
Study 11477496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sugar diet (LSD) providing 5% of energy from sucrose
Number of subjects: 95
Study 11477496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-containing diet (SCD) providing 10% of energy from sucrose
Number of subjects: 95
Study 9566175 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher for free mammography
Number of subjects: 0
Study 9566175 — intervention group
Group type: COMPARATOR
Intervention: Control group (women living in the same counties without vouchers)
Number of subjects: 0
Study 8311217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel applied to Filshie clips
Number of subjects: 62
Study 8311217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lignocaine gel)
Number of subjects: 62
Study 2031737 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet of advice for parents
Number of subjects: 0
Study 6779334 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 10
Study 6779334 — intervention group
Group type: COMPARATOR
Intervention: diazepam 2 mg
Number of subjects: 10
Study 6779334 — intervention group
Group type: COMPARATOR
Intervention: diazepam 5 mg
Number of subjects: 10
Study 6779334 — intervention group
Group type: COMPARATOR
Intervention: diazepam 10 mg
Number of subjects: 10
Study 6779334 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31436452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic-listening task training
Number of subjects: 75
Study 31436452 — intervention group
Group type: COMPARATOR
Intervention: Auditory duration discrimination task (Control)
Number of subjects: 75
Study 31334703 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day and EPA 1,800 mg/day
Number of subjects: 50
Study 31334703 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 2.5 mg/day
Number of subjects: 50
Study 29100524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 22
Study 29100524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine with magnesium sulfate
Number of subjects: 22
Study 29100524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25666295 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus cetuximab
Number of subjects: 152
Study 24032427 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 223
Study 24032427 — intervention group
Group type: COMPARATOR
Intervention: No-Adrenaline
Number of subjects: 223
Study 21857944 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day) for three days prior to oGTT testing
Number of subjects: 15
Study 19039620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration (0.4 mg)
Number of subjects: 18
Study 19039620 — intervention group
Group type: COMPARATOR
Intervention: Head-up tilt test (HUT)
Number of subjects: 18
Study 17215529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks without treatment)
Number of subjects: 750
Study 17215529 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (9 MU subcutaneously three times weekly)
Number of subjects: 750
Study 14756383 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg oral)
Number of subjects: 12
Study 14756383 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (200 mg oral)
Number of subjects: 12
Study 11466256 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 153
Study 11466256 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 153
Study 11466256 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 153
Study 11466256 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs (Timolol, Betaxolol, Carteolol)
Number of subjects: 153
Study 11466256 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual fields analysis
Number of subjects: 153
Study 9568218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30
Study 9568218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7921931 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intermuscular wound infusion with 0.25% bupivacaine
Number of subjects: 10
Study 7921931 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 3360173 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg norethisterone (NE)
Number of subjects: 24
Study 3360173 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg norethisterone (NE)
Number of subjects: 24
Study 31587622 — intervention group
Group type: EXPERIMENTAL
Intervention: RE+HRE
Number of subjects: 40
Study 31587622 — intervention group
Group type: COMPARATOR
Intervention: RE
Number of subjects: 40
Study 29782075 — intervention group
Group type: COMPARATOR
Intervention: Standard Care group
Number of subjects: 912
Study 29114516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization
Number of subjects: 44
Study 29114516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic strengthening
Number of subjects: 44
Study 29114516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 44
Study 26330412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Number of subjects: 15179
Study 26330412 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 15179
Study 26330412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Ezetimibe/simvastatin and Simvastatin)
Number of subjects: 15179
Study 23985232 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowing ≥ 5 quitters
Number of subjects: 430
Study 23985232 — intervention group
Group type: COMPARATOR
Intervention: Knowing no quitters
Number of subjects: 430
Study 21205113 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucose (0.3 mg/kg)
Number of subjects: 9
Study 21205113 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fructose (0.3 mg/kg)
Number of subjects: 9
Study 21205113 — intervention group
Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 9
Study 18496342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 25
Study 18496342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16278102 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care skills training (Expert Patients Programme)
Number of subjects: 0
Study 16278102 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 14592361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 10932370 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS)
Number of subjects: 5778
Study 10932370 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 5778
Study 8824693 — intervention group
Group type: COMPARATOR
Intervention: 12 mg spirapril (first dose)
Number of subjects: 24
Study 8824693 — intervention group
Group type: COMPARATOR
Intervention: 12 mg spirapril (chronic treatment)
Number of subjects: 24
Study 8824693 — intervention group
Group type: COMPARATOR
Intervention: 3 mg spirapril
Number of subjects: 24
Study 8824693 — intervention group
Group type: COMPARATOR
Intervention: 12 mg spirapril
Number of subjects: 24
Study 1358158 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylamino-phenoxy-propanol-acetate (BPPA)
Number of subjects: 12
Study 1358158 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 12
Study 1358158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3918993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg/day, increased to 100-300 mg/day)
Number of subjects: 101
Study 3918993 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (50 mg/day, increased to 100-300 mg/day)
Number of subjects: 101
Study 3918993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 30964824 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurately measured office blood pressure (OBP)
Number of subjects: 919
Study 30964824 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP)
Number of subjects: 919
Study 29357293 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mandibular advancement splint (MAS)
Number of subjects: 18